Childhood osteomyelitis-incidence and differentiation from other acute onset musculoskeletal features in a population-based study

Riise, Øystein Rolandsen; Kirkhus, Eva; Handeland, Kai Samson; Flatø, Berit; Reiseter, Tor; Cvancarova, Milada; Nakstad, Britt; Wathne, Karl‐Olaf

doi:10.1186/1471-2431-8-45

Cited by 172 publications

(139 citation statements)

References 44 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…The most common etiology in children is hematogenous infections. Previous studies from Norway 32,33 and Lithuania 34 have noted an annual incidence of approximately ten to fourteen cases of hematogenous osteomyelitis per 100,000 children. On the other hand, a lower incidence of acute hematogenous osteomyelitis has been reported in Scotland in two separate studies of the Glasgow population between 1970 and 1997, with an annual incidence of 2.9 new cases per 100,000 population 35,36 .…”

Section: Discussionmentioning

confidence: 99%

Trends in the Epidemiology of Osteomyelitis

Kremers

Nwojo

Ransom

et al. 2015

The Journal of Bone and Joint Surgery

341

211

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in the Epidemiology of Osteomyelitis

Kremers

Nwojo

Ransom

et al. 2015

The Journal of Bone and Joint Surgery

341

211

View full text Add to dashboard Cite

show abstract

“…Subacute OM appears to be have increased in recent years, 10 and is reported to be 5 per 100,000 children in Norway. 11 Neonatal infection can occur in preterm or term-born babies and is associated with a wider range of causative organisms (see below) 12 and potential complications. Neonatal vascular anatomy allows infection within the bone to reach the growth plate or joint in 76% of neonatal osteomyelitis cases.…”

Section: Osteomyelitis and Septic Arthritis In Childrenmentioning

confidence: 99%

Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Sukhtankar

Arch

Ahmad

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Declared competing interests of authors: Saul N Faust was UK chief investigator and University Hospital Southampton NHS Foundation Trust principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All funds were paid into accounts within the NHS trust or university and not paid as personal fees. He reports consultancy fees for advisory board participation paid into accounts within the NHS trust or university (not personal fees) from vaccine manufacturers and antimicrobial agent manufacturers, including AstraZeneca, Cubist, Merck, GlaxoSmithKline (GSK) and Pfizer, outside the submitted work. He acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/ University of Southampton that are sponsored by vaccine manufacturers and antimicrobial agents, and has participated in advisory boards for vaccine manufacturers. Adam Finn reports grants and personal fees from Sanofi Pasteur MSD Ltd (SPMSD), and grants and personal fees from GSK, outside the submitted work. In addition, prior to October 2014, the University of Bristol and University Hospitals Bristol NHS Foundation Trust received funding for research conducted by Adam Finn and for consultancy and lectures from Pfizer, GSK, SPMSD and Novartis, who manufacture licensed and developmental meningococcal vaccines. Stuart C Clarke acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receive no personal payments from them. He has participated in advisory boards for vaccine manufacturers and has received financial assistance from vaccine manufacturers to attend conferences, but receives no personal payments for this work. All grants and honoraria are paid into accounts within the respective NHS trusts or universities. Jethro Herberg reports that he was an investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis; he received no personal payments. Andrew Riordan reports that the trust, but not he, has received funding for research sponsored by vaccine manufacturers and antimicrobial agents. He was lead editor for an e-learning package on meningitis produced by the Royal College of Paediatric and Child Health, funded by an unrestricted grant from Novartis Vaccines. Marieke Emonts was Newcastle upon Tyne Hospitals Foundation Trust's principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All grants and honoraria are paid into accounts within the NHS trust or university; she received no personal payment of any kind. Marieke Emonts reports acting as site principle investigator on behalf of the Newcastle upon Tyne Hospitals Foundation Trust/Newcastle University for clinical tr...

show abstract

“…Infection typically occurs in children, and is commonly caused by invasion of the richly vascularized metaphyseal region of the tibia, femur, or humerus by a single microorganism (Claro et al, 2011). Previous studies have suggested that the frequency of acute osteomyelitis is higher in children in Saudi Arabia than in other parts of the world (Blyth et al, 2001;Riise et al, 2008;Al Hajry et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Association of single nucleotide polymorphisms in pro-inflammatory cytokine and toll-like receptor genes with pediatric hematogenous osteomyelitis

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. Hematogenous osteomyelitis (H O ) is a bone infectionwherein bacteria penetrate to the bone through the blood stream. Several single nucleotide polymorphisms (SNPs) have been associated with susceptibility to infectious diseases. In this study, we investigated the contribution of SNPs in interleukin (IL)-1B1 (rs16944), IL1A (rs1800587), IL1B (rs1143634), toll-like receptor (TLR)-2 (rs3804099), TLR4 (rs4986790), TLR4 (rs4986791), IL1R (rs2234650), tumor necrosis factor (TNF)-α (rs1800629), TNF (rs361525), and IL1RN (rs315952) towards the development of H O in Saudi patients and compared to healthy controls. Fifty-two patients diagnosed with H O and 103 healthy individuals were genotyped. The frequencies of genotypes GG (rs16944) and AA (rs16944) were lower and higher in patients [odds ratio (OR) = 0.34, Pc = 0.05] and controls (OR = 1.33, Pc = 0.05), respectively, suggesting that SNPs at this locus could alter H O susceptibility. In addition, the patients and controls exhibited lower and higher frequencies of the alleles G (rs16944) (OR = 0.43, Pc = 0.007) and A (rs16944) (OR = 2.32, Pc = 0.007), respectively. The expression of alleles C (rs3804099) and T (rs3804099) were higher in patients (OR = 2.05, Pc = 0.04) and controls (OR = 0.49, Pc = 0.04), respectively. In conclusion, SNPs at rs16944 and rs3804099 were found to be associated with H O in the Saudi population.

show abstract

Childhood osteomyelitis-incidence and differentiation from other acute onset musculoskeletal features in a population-based study

Cited by 172 publications

References 44 publications

Trends in the Epidemiology of Osteomyelitis

Trends in the Epidemiology of Osteomyelitis

Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Association of single nucleotide polymorphisms in pro-inflammatory cytokine and toll-like receptor genes with pediatric hematogenous osteomyelitis

Contact Info

Product

Resources

About